As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Oyster Point Pharma, Inc.

Viatris is a global healthcare company that produces high-quality medicines across a range of therapeutic areas, including both noncommunicable and infectious diseases.

Viatris

Pharmaceutical Manufacturing

Oyster Point Pharma | 11,747 followers on LinkedIn. Commercial-stage biopharmaceutical company focused on pharmaceutical therapies to treat ophthalmic diseases. | Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

Kelly R.

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
revenue					24.54M -
cost of revenue					1.52M -
gross profit					23.01M -
selling and marketing expenses					54.62M -
general and administrative expenses	2.05M -	2.98M 45.34%	13.67M 358.67%	31.18M 128.03%	40.81M 30.90%
selling general and administrative expenses	2.05M -	2.98M 45.34%	13.67M 358.67%	31.18M 128.03%	95.44M 206.10%
research and development expenses	3.63M -	13.76M 278.72%	33.63M 144.48%	39.81M 18.39%	24.23M 39.13%
other expenses
cost and expenses	5.68M -	16.74M 194.49%	47.30M 182.63%	70.99M 50.08%	121.19M 70.72%
operating expenses	5.68M -	16.74M 194.49%	47.30M 182.63%	70.99M 50.08%	119.67M 68.57%
interest expense	488K -				3.73M -
ebitda	-6.11M -	-16.50M 169.97%	-45.69M 176.87%	-70.06M 53.33%	-96.78M 38.15%
operating income	-5.68M -	-16.74M 194.49%	-47.30M 182.63%	-70.99M 50.08%	-96.92M 36.54%
depreciation and amortization	-430K -	233K 154.19%	19K 91.85%	461K 2,326.32%	141K 69.41%
total other income expenses net	-918K -	233K 125.38%	1.59M 582.40%	469K 70.50%	-3.73M 896.16%
income before tax	-6.60M -	-16.50M 150.01%	-45.71M 176.99%	-70.52M 54.27%	-100.66M 42.74%
income tax expense			1.59M -	469K 70.50%	3.73M 696.16%
net income	-6.60M -	-16.50M 150.01%	-45.71M 176.99%	-70.52M 54.27%	-104.39M 48.03%
weighted average shs out	9.02M -	9.02M 0%	4.59M 49.19%	24.13M 426.23%	26.04M 7.91%
weighted average shs out dil	9.02M -	9.02M 0%	4.59M 49.19%	24.13M 426.23%	26.04M 7.91%
eps	-0.73 -	-1.83 150.68%	-9.97 444.81%	-2.92 70.71%	-4.01 37.33%
epsdiluted	-0.73 -	-1.83 150.68%	-9.97 444.81%	-2.92 70.71%	-4.01 37.33%

COM:OYSTERPOINTRX

Viatris

Last Close

11.17

30/12 21:00

Volume Today

2.09M

Avg: -

Preview